Form 4: Agilon Health Executive Girish Venkatachaliah Reports Stock and Option Transactions
SEC Form 4
Girish Venkatachaliah, Chief Technology Officer of Agilon Health, reported the acquisition and disposal of common stock and the acquisition of options on April 1, 2025.
Summary
- On April 1, 2025, Girish Venkatachaliah, the Chief Technology Officer of Agilon Health, reported transactions involving the company's stock and options.
- Venkatachaliah acquired 122,550 shares of common stock at $0 and disposed of 277,670 shares.
- Following these transactions, Venkatachaliah beneficially owns 277,670 shares of common stock.
- Additionally, Venkatachaliah acquired 192,308 options with an exercise price of $4.08, exercisable starting April 1, 2025, and expiring on April 1, 2035.
- These options vest in three equal installments on each anniversary of April 1, 2025, subject to continued employment.
- Following the transaction, Venkatachaliah directly owns 192,308 options.
- The report was filed on April 3, 2025, by Mimi Yang as Attorney-in-Fact.
Sentiment
Score: 5
Explanation: This is a neutral report of insider transactions, with no inherent positive or negative implications. It simply reflects the executive's stock and option activity.
Future Outlook
The restricted stock units and options vest over time, contingent on continued employment.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their transactions in the company's securities. It allows investors to monitor the actions of key executives and their alignment with shareholder interests.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies and their executives.
- The vesting schedules and option grants are typical forms of executive compensation, aligning with industry norms for incentivizing performance and retention.
- Companies like UnitedHealth Group (UNH) and Humana (HUM) also utilize stock options and restricted stock units as part of their executive compensation packages.
Stakeholder Impact
- Shareholders can use this information to understand executive compensation and alignment with company performance.
Key Dates
| Date | Description |
|---|---|
| 04/01/2025 | Date of earliest transaction: Acquisition and disposal of common stock and acquisition of options. |
| 04/01/2025 | Vesting start date for restricted stock units and options. |
| 04/01/2035 | Expiration date for options. |
| 04/03/2025 | Date of Form 4 filing. |
Keywords
Agilon Health, Girish Venkatachaliah, stock options, Form 4, insider trading, executive compensation, AGL
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.